Does the amylin component change the side-effect profile or only the effect size?

This matters because it predicts what a related molecule should do.

I would like the axes of comparison first and the recommendation second.

I have tried the first option and it works; the question is whether the second is better rather than merely different.

Is there a defensible reason to prefer one, or is this a coin flip?

Answer first: a fixed combination of cagrilintide, a long-acting amylin analogue, with semaglutide — two mechanisms, two receptors, one weekly injection.

The amylin receptor is the calcitonin receptor in complex with a receptor-activity-modifying protein, so the pharmacology is genuinely distinct from anything in the incretin class.

The glycaemic component in the diabetes population behaves differently from the weight component, and the two trials in the programme should be read separately.

Both components hit the area postrema, which is why titration is careful.

Amylin is a separate hormone with a separate receptor complex, which is why this is a genuine combination rather than a dose increase.

The pre-trial expectation in some quarters had drifted towards twenty-five per cent, so a result above every comparator was received as a shortfall. That is a lesson about expectations rather than about the compound.

REDEFINE-1 reported mean weight reduction around twenty-two to twenty-three per cent at 68 weeks in adults with obesity and without diabetes, against roughly sixteen per cent for semaglutide alone and about eleven for cagrilintide alone in the same trial.

Pramlintide, the older amylin analogue, provides the long-term clinical experience with amylin agonism, at a very different dosing frequency.

Two mechanisms, two receptors, one injection. That is the design.

This is a good example of expectation management: a strong result read as a disappointment because the pre-trial expectation had drifted.

Cagrilintide is an acylated long-acting amylin analogue designed for weekly administration; semaglutide is the GLP-1 agonist component. The receptors are unrelated, which is the basis for additivity.

The expectation gap is a story about expectations, not about the pharmacology.

Start with the rationale: amylin acts on satiation through the area postrema and the incretin acts on appetite and glycaemia, so the combination is additive by design rather than by hope.

Both components act at the area postrema, so the gastrointestinal tolerability profile is not simply the sum of the two and the titration schedule reflects that.

The REDEFINE programme is the appropriate citation for combination results, with REDEFINE-1 in obesity without diabetes and further trials in other populations.

Fixed combination means fixed ratio. That is a real constraint.